Home » Stocks » ALEC

Alector, Inc. (ALEC)

Stock Price: $9.53 USD -0.18 (-1.85%)
Updated Oct 30, 2020 4:00 PM EDT - Market closed
After-hours: $9.41 -0.12 (-1.26%) Oct 30, 4:13 PM

Stock Price Chart

Key Info

Market Cap 755.37M
Revenue (ttm) 19.04M
Net Income (ttm) -147.61M
Shares Out 79.26M
EPS (ttm) -2.04
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 30, 2020
Last Price $9.53
Previous Close $9.71
Change ($) -0.18
Change (%) -1.85%
Day's Open 9.51
Day's Range 9.12 - 9.55
Day's Volume 527,474
52-Week Range 9.12 - 35.93

More Stats

Market Cap 755.37M
Enterprise Value 296.96M
Earnings Date (est) Nov 17, 2020
Ex-Dividend Date n/a
Shares Outstanding 79.26M
Float 55.96M
EPS (basic) -2.04
EPS (diluted) -2.04
FCF / Share -1.83
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 10.67M
Short Ratio 8.51
Short % of Float 19.07%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 39.68
PB Ratio 2.17
Revenue 19.04M
Operating Income -155.16M
Net Income -147.61M
Free Cash Flow -143.68M
Net Cash 458.40M
Net Cash / Share 5.78
Gross Margin -416.58%
Operating Margin -814.99%
Profit Margin -775.30%
FCF Margin -754.70%
ROA -18.48%
ROE -49.12%
ROIC -37.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (9)

Buy 9
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(266.00% upside)
Current: $9.53
Target: 34.88
*Average 12-month price target from 8 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth-23.33%641.02%797.84%-
Gross Profit21.2227.683.740.42
Operating Income-114-57.29-32.68-15.13
Net Income-105-52.25-32.48-15.11
Shares Outstanding61.7311.309.147.17
Earnings Per Share-1.71-4.62-3.55-2.11
Operating Cash Flow-99.31127-17.77-12.99
Capital Expenditures-15.27-1.88-0.80-2.25
Free Cash Flow-115126-18.57-15.24
Cash & Equivalents35529232.4551.04
Total Debt48.04---
Net Cash / Debt30729232.4551.04
Book Value195-97.40-52.03-24.91
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Alector, Inc.
Country United States
Employees 153
CEO Arnon Rosenthal

Stock Information

Ticker Symbol ALEC
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ALEC
IPO Date February 7, 2019


Alector, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in phase II clinical trial for the treatment of frontotemporal dementia disease; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002 and AL003, which are in phase 1b clinical trial for the treatment of Alzheimer's disease. In addition, it has 10 programs under research and development stage. The company has a collaboration agreement with Adimab, LLC for the research and development of antibodies. Alector, Inc. was founded in 2013 and is headquartered in South San Francisco, California.